Reducing effect of mangiferin on serum uric acid levels in mice

References

• Bomalaski JS, Clark MA. (2004). Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep, 6, 240–247.
   PubMedGoogle Scholar
• Burkhardt S, Reiter RJ, Tan DX, Hardeland R, Cabrera J, Karbownik M. (2001). DNA oxidatively damaged by chromium(III) and H(2)O(2) is protected by the antioxidants melatonin, N(1)-acetyl-N(2)-formyl-5-methoxykynuramine, resveratrol and uric acid. Int J Biochem Cell Biol, 33, 775–783.
   PubMed Web of Science ®Google Scholar
• Campion EW, Glynn RJ, DeLabry LO. (1987). Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med, 82, 421–426.
   PubMedGoogle Scholar
• Carroll JJ, Coburn H, Douglass R, Babson AL. (1971). A simplified alkaline phosphotungstate assay for uric acid in serum. Clin Chem, 17, 158–160.
   PubMed Web of Science ®Google Scholar
• Cazzaniga G, Terao M, Lo Schiavo P, Galbiati F, Segalla F, Seldin MF, Garattini E. (1994). Chromosomal mapping, isolation, and characterization of the mouse xanthine dehydrogenase gene. Genomics, 23, 390–402.
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. (2000). Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA, 283, 2404–2410.
   PubMed Web of Science ®Google Scholar
• García D, Delgado R, Ubeira FM, Leiro J. (2002). Modulation of rat macrophage function by the Mangifera indica L. extracts Vimang and mangiferin. Int Immunopharmacol, 2, 797–806.
   PubMed Web of Science ®Google Scholar
• Ge DD, Zhang Y, Liu EW, Wang T, Hu LM. (2011). Chemical constituents of Mangifera indica leaves (I). Chin Trad Herb Drugs, 42, 428–431.
   Google Scholar
• Hair PI, McCormack PL, Keating GM. (2008). Febuxostat. Drugs, 68, 1865–1874.
   PubMed Web of Science ®Google Scholar
• Hall AP, Barry PE, Dawber TR, McNamara PM. (1967). Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med, 42, 27–37.
   PubMed Web of Science ®Google Scholar
• Hall IH, Scoville JP, Reynolds DJ, Simlot R, Duncan P. (1990). Substituted cyclic imides as potential anti-gout agents. Life Sci, 46, 1923–1927.
   PubMed Web of Science ®Google Scholar
• Hayden MR, Tyagi SC. (2004). Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond), 1, 10.
   PubMedGoogle Scholar
• Ichida K, Amaya Y, Noda K, Minoshima S, Hosoya T, Sakai O, Shimizu N, Nishino T. (1993). Cloning of the cDNA encoding human xanthine dehydrogenase (oxidase): Structural analysis of the protein and chromosomal location of the gene. Gene, 133, 279–284.
   PubMed Web of Science ®Google Scholar
• Ichiki H, Miura T, Kubo M, Ishihara E, Komatsu Y, Tanigawa K, Okada M. (1998). New antidiabetic compounds, mangiferin and its glucoside. Biol Pharm Bull, 21, 1389–1390.
   PubMed Web of Science ®Google Scholar
• Kong L, Zhou J, Wen Y, Li J, Cheng CH. (2002). Aesculin possesses potent hypouricemic action in rodents but is devoid of xanthine oxidase/dehydrogenase inhibitory activity. Planta Med, 68, 175–178.
   PubMed Web of Science ®Google Scholar
• Liese AD, Hense HW, Löwel H, Döring A, Tietze M, Keil U. (1999). Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology, 10, 391–397.
   PubMed Web of Science ®Google Scholar
• Minoshima S, Wang Y, Ichida K, Nishino T, Shimizu N. (1995). Mapping of the gene for human xanthine dehydrogenase (oxidase) (XDH) to band p23 of chromosome 2. Cytogenet Cell Genet, 68, 52–53.
   PubMedGoogle Scholar
• Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ. (2006). A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 290, F625–F631.
   PubMed Web of Science ®Google Scholar
• Puddu PE, Lanti M, Menotti A, Mancini M, Zanchetti A, Cirillo M, Angeletti M, Panarelli W; Gubbio Study Research Group. (2001). Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population study. Acta Cardiol, 56, 243–251.
   PubMed Web of Science ®Google Scholar
• Reinders MK, Jansen TL. (2010). Management of hyperuricemia in gout: Focus on febuxostat. Clin Interv Aging, 5, 7–18.
   PubMed Web of Science ®Google Scholar
• Schlesinger N. (2004). Management of acute and chronic gouty arthritis: Present state-of-the-art. Drugs, 64, 2399–2416.
   PubMed Web of Science ®Google Scholar
• Shoji A, Yamanaka H, Kamatani N. (2004). A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum, 51, 321–325.
   PubMed Web of Science ®Google Scholar
• Singh S, Farhan Asad S, Hadi SM. (1998). Uric acid inhibits l-DOPA-CU(II) mediated DNA cleavage. Neurosci Lett, 258, 69–72.
   PubMed Web of Science ®Google Scholar
• Stavric B, Clayman S, Gadd RE, Hébert D. (1975). Some in vivo effects in the rat induced by chlorprothixene and potassium oxonate. Pharmacol Res Commun, 7, 117–124.
   PubMedGoogle Scholar
• Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, Odaka M, Yamaguchi M, Yosida H, Morisawa H, Murayama T. (2000). Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol, 10, 403–409.
   PubMedGoogle Scholar
• Yamada H, Kotaki H, Furitsu H, Sawada Y, Iga T. (1999). Mechanism of the uricosuric action of the anti-inflammatory drug E3040 used to treat inflammatory bowel disease I: Study using a rat model of hyperuricemia. Biopharm Drug Dispos, 20, 77–83.
   PubMed Web of Science ®Google Scholar
• Yonetani Y, Iwaki K. (1983). Effects of uricosuric drugs and diuretics on uric acid excretion in oxonate-treated rats. Jpn J Pharmacol, 33, 947–954.
   PubMedGoogle Scholar
• Yoshikawa M, Ninomiya K, Shimoda H, Nishida N, Matsuda H. (2002). Hepatoprotective and antioxidative properties of Salacia reticulata: Preventive effects of phenolic constituents on CCl4-induced liver injury in mice. Biol Pharm Bull, 25, 72–76.
   PubMed Web of Science ®Google Scholar
• Yoshimi N, Matsunaga K, Katayama M, Yamada Y, Kuno T, Qiao Z, Hara A, Yamahara J, Mori H. (2001). The inhibitory effects of mangiferin, a naturally occurring glucosylxanthone, in bowel carcinogenesis of male F344 rats. Cancer Lett, 163, 163–170.
   PubMed Web of Science ®Google Scholar